louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00953628: Endometrial Advancement After Rec or u-HCG Triggering
Official title: Endometrial Advancement After Rec or u-HCG Triggering
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Keywords: endometrium
histology
pregnancy
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: Merck Serono International SA
First posted: 2009-08-06
Enrollment: 130
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

Detailed description: Biopsies of endometrium were taken in different groups Pregnancy rates were compared among defferent groups

Eligibility criteria: Inclusion Criteria:

* Less than 36 years old
* Male or tubal infertility
* FSH\<12 on day 3

Exclusion Criteria:

* Endometriosis stage 3 \& 4

Primary outcomes:
measure: endometrium histology on the day of OPU
timeFrame: day of oocytre pick up
Secondary outcomes:
measure: pregnancy rate
timeFrame: 14 days after oocyte pick up
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Centre for Reproductive Medicine, UZ Brussel
state: Jette
Study officials:
affiliation: Professor or OB-GYN
name: Paul Devroey, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03279328: Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents
Official title: Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Actinic Keratoses
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2017-09-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This proposed project will be an open-label, split face, randomized controlled pilot study. Up to 60 patients with diffuse facial actinic keratosis will be enrolled in the study. The purpose of this study is to understand the change in skin appearance throughout 5-FU treatment course and to examine whether a topical corticosteroid and moisturizer can decrease severity and duration of skin inflammation after 5-FU treatment course.

Detailed description: The purpose of this study to understand the change in skin appearance during and after the course of 5-FU cream in patients with AK, and compare how the appearance of skin inflammation changes with the use of topical corticosteroids and moisturizers.

Eligibility criteria: Inclusion Criteria:

* Male and female, at least 18 years of age
* Subject must have a diagnosis of actinic keratosis (at least 5 lesions on each side of the face)
* Able to comprehend and read the English language

Exclusion Criteria:

* Subjects who do not fit the inclusion criteria
* Concurrently have other inflammatory skin conditions.
* Prior known allergy to any components to of 5FU cream, topical steroid ointment or vaseline.

  • Subject who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures (i.e.: compliant with using 5-FU cream, topical corticosteroid or moisturizers
* Those that are prisoners or cognitively impaired.

Primary outcomes:
measure: Skin barrier biophysical properties
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona - Banner University Medicine Dermatology
state: Arizona
Study officials:
References:
Clinical trial NCT06962228: Cross-cultural Adaptation of the Chinese Version of QoLAF-Q (Quality of Life in Patients With Anal Fistula Questionnaire) ：A Multi-center Study
Official title: A Multicenter Observational Cross-sectional Clinical Trial of Cross-cultural Adaptation of the Chinese Version of QoLAF-Q (Quality of Life in Patients With Anal Fistula Questionnaire)
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Anal Fistula
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
First posted: 2025-05-08
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: anal fistula patients who visited the anorectal surgery wards and outpatient departments of tertiary hospitals across the country

Brief summary: The investigators verify the reliability and practicality of the Chinese adaptation results of QoLAF-Q, which helps Chinese doctors better master the methods and techniques of quality of life assessment.

Detailed description: When the investigators conduct cross-cultural adaptation to verify the applicability of QoLAF-Q in China, the investigators also compare it with the cross-cultural adaptation results of other language versions of this scale. While verifying the reliability and practicality of the Chinese adaptation results of QoLAF-Q, the investigators also explore its differences, which helps Chinese doctors better master the methods and techniques of quality of life assessment, pay more attention to the physical and mental health of patients, improve the quality of life and satisfaction of patients, and provide a reference for the development of more scientific, effective, and practical scales.

Eligibility criteria: Inclusion Criteria:

1. meeting the diagnostic criteria for anal fistula in the "Diagnostic Criteria for Anal Fistula (2004 Edition)", and being diagnosed through clinical examinations, digital rectal examinations, anorectal ultrasound, MRI, and other examinations;
2. being 18 years old or above;
3. having clear consciousness and being able to understand and cooperate to complete the questionnaire survey;
4. voluntarily signing the informed consent form.

Exclusion Criteria:

1. having other serious anorectal diseases, such as anal fissure, rectal prolapse, colorectal cancer, etc.;
2. having severe dysfunction of important organs such as the heart, liver, and kidneys;
3. suffering from mental diseases or having cognitive impairments;
4. having undergone anorectal surgery or other major surgeries that may affect the quality of life recently (within 3 months).

Primary outcomes:
measure: Cronbach's α coefficient
timeFrame: immediately after filling out the questionnaires
Secondary outcomes:
measure: KMO value
timeFrame: immediately after filling out the questionnaires
measure: Factor analysis of QoLAF-Q(quality of life in patients with anal fistula questionnaire)
timeFrame: immediately after filling out the questionnaires
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00849628: Use of Drugs and Constipation in Nursing Homes
Official title: Use of Drugs and Constipation in Nursing Homes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Constipation
Diarrhea
Keywords: Aged
Polypharmacy
Adverse effects
Nursing homes
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Sykehuset Innlandet HF
First posted: 2009-02-24
Enrollment: 267
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents in nursing homes

Brief summary: The purpose of this study is to study factors (drugs, serum concentration of drugs, nutrition, physical activity, demographics, diseases etc.) related to constipation and diarrhea in nursing homes, and the effect of different laxative regimens.


Eligibility criteria: Inclusion Criteria:

* Above 60 years old
* Stayed in nursing homes for more than 8 weeks
* Informed consent

Exclusion Criteria:

* Expected discharge within 2 weeks
* Organic disorders causing constipation and diarrhea

Primary outcomes:
measure: Prevalence of constipation
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Gjøvik
country: Norway
facility: Innlandet Hospital Trust
state: Oppland
Study officials:
affiliation: Sykehuset Innlandet HF
name: Per G Farup, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fosnes GS, Lydersen S, Farup PG. Drugs and constipation in elderly in nursing homes: what is the relation? Gastroenterol Res Pract. 2012;2012:290231. doi: 10.1155/2012/290231. Epub 2012 Feb 29.
Clinical trial NCT03205228: Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
Official title: Treatment Outcomes in Patients With Globus: A Randomized Control Trial of Psychoeducation, Anxiolytics and Proton Pump Inhibitors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Globus
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2017-07-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized controlled trial study is conducted to compare treatment efficacy between psycho-education, anxiolytics drug and proton pump inhibitors in participants who met the criteria of globus.

Detailed description: This is a randomized controlled trial in patients with globus. All participants will be allocated into 3 groups (16 subjects/group) : Proton pump inhibitors (miracid®) , anxiolytics drug (Deanxit®) and psycho-education. The study duration is 4 weeks long.

Data regarding clinical severity and quality of life of all participants will be collected at the beginning and at the end of treatment.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Symptoms based on the following criteria: Persistent or intermittent nonpainful sensation of a lump or foreign body in the throat with no structural lesion identified on physical examination, laryngoscopy, or endoscopy.

  1. Occurrence of the sensation between meals.
  2. Absence of dysphagia or odynophagia

Exclusion Criteria:

* Subjects with psychological disease
* Significant heart disease and/or arrhythmia
* Proton Pump inhibitors and/or Histamine 2 Receptor Antagonist use within 2 weeks before randomization
* Mono-amine Oxidase inhibitors or Selective Serotonin Reuptake Inhibitor or Tricyclic antidepressant use within 2 weeks before randomization
* History of drug allergy that use in research
* Pregnancy or breast feeding
* Decline to participate in study

Primary outcomes:
measure: Clinical improvement
timeFrame: 28 days
Secondary outcomes:
measure: Improvement in quality of life
timeFrame: 28 days
Other outcomes:
Locations:
city: Bangkok Noi
country: Thailand
facility: Division of gastroenterology, Department of Medicine, Siriraj hospital
state: Bangkok,
Study officials:
affiliation: Mahidol University
name: Monthira Maneerattanaporn, MD., MS.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01406028: Does Emotional Support Decrease In Vitro Fertilization Stress?
Official title: Does Emotional Support During the Luteal Phase Decrease the Stress of IVF?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: In Vitro Fertilization
Psychological Stress
Keywords: IVF
Stress
Infertility
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2011-07-29
Enrollment: 131
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In vitro fertilization for infertility has been associated with a significant amount of treatment related stress for patients. In addition,stress levels increase between embryo transfer and pregnancy test, during this waiting period. The investigators evaluated whether or not brief interventions by phone by trained social workers influenced stress levels. Our data showed that these interventions did not change levels, but confirmed that stress did increase during this time and that patients report wanting additional emotional support to improve stress during this period.


Eligibility criteria: Inclusion Criteria:

* All women (ages 18-45) undergoing their first fresh cycle of IVF using autologous oocytes where an embryo transfer occurred

Exclusion Criteria:

* \> 2nd cycle of IVF IVF using donor eggs or a gestational carrier
* Transfers with Cryopreserved embryos
* Day 5 embryo transfers
* Self-reported history of depression or anxiety
* Already seeing a mental health professional
* Inability to speak or read English

Primary outcomes:
measure: Perceived Stress Scale Scores
timeFrame: Day of embryo transfer (day 1) and 10 days later
Secondary outcomes:
measure: Patient perceived benefit
timeFrame: 10 days after embryo transfer
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT06706128: Reflex Rolling Versus Lung Squeezing Techniques On Pulmonary Functions In Premature Neonate With Pneumonia
Official title: Reflex Rolling Versus Lung Squeezing Techniques On Pulmonary Functions In Premature Neonate With Pneumonia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumonia
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2024-11-26
Enrollment: 24
Sex: ALL
Minimum age (years): 5
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Respiratory problems in neonates are one of the leading causes of neonatal morbidity and mortality in developing countries. These respiratory problems are seen in premature neonates, which mainly include respiratory distress syndrome (RDS), pneumonia, requiring ventilatory assistance or oxygen support

Detailed description: The purpose of this study is to compare between the effect of reflex rolling and lung squeezing techniques on pulmonary functions in premature neonates with pneumonia.

Eligibility criteria: Inclusion Criteria:

* 1) Preterm neonates with pneumonia. 2) Neonates with 30-37 weeks of gestation admitted to NICU. 3) They were free from any major congenital malformation. 4) They were clinically and thermodynamically stable.

Exclusion Criteria:

* 1) Treatment with neurotropic drugs. 2) Interventricular hemorrhage. 3) Temperature \>38 4) Respiratory and cardiac congenital anomalies. 5) Seizures. 6) Surgical procedures. 7) Genetic Disorders 8) Any segmental or lobar collapse confirmed on chest x-ray. 9) Major airway interventions including change of endo-tracheal tube, hand ventilation or bronchial lavage in the previous 12 hours.

Primary outcomes:
measure: Respiratory Rate
timeFrame: Respiratory Rate measured at day (0) at after 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gamasa
country: Egypt
facility: Delta University for Science and Technology
state: Dakahelia
Study officials:
References:
Clinical trial NCT05125328: ANI and Remifentanil in Skull Pin Fixation.
Official title: To Explore the Optimal Dose of Remifentanil for Skull Pin Fixation in Intracranial Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain, Procedural
Keywords: remifentanil
pain
analgesia nociception index
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2021-11-18
Enrollment: 27
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Forty patients were enrolled, and all patients used total intravenous anesthesia (remifentanil-propofol based total intravenous analgesia) as anesthesia induction and maintenance. According to the preliminary data of this department, patients who underwent intracranial surgery for skull pin fixation used remifentanil 5.0-6.0 ng/ml, while the hemodynamics is relatively stable. Therefore, when this plan is implemented, the patient needs to be under the same depth of anesthesia (monitored by electroencephalography, maintaining a value of 40-60), first start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An Analgesia Nociception Index(ANI) lower than 30 and hyperdynamics (the increased heart rate(HR) and mean blood pressure(MBP) up 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.

Data collection: Heart Rate, Measure blood pressure, Analgesia Nociception Index, Bispectral index, concentrations of propofol and remifentanil before 2 mins, during, 5, and 15 mins of skull pin fixation were recorded and analyzed.


Eligibility criteria: Inclusion Criteria:

1. Must be at least 20 years old and less than 80 years old
2. With anesthesia risk grade below grade three (including grade three) (ASA I\~III)
3. Patients who are expected to undergo intracranial surgery for skull pin fixation

Exclusion Criteria:

1. Those with anesthesia risk classification ASA class IV or higher
2. Those who are allergic to opioid analgesics or propofol drugs
3. Emergency patients

Primary outcomes:
measure: 50% effect concentration of remifentanil
timeFrame: peri-fixation period
measure: 90% effect concentration of remifentanil
timeFrame: peri-fixation period
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
Study officials:
References:
Clinical trial NCT00051428: The Efficacy of Reiki in the Treatment of Fibromyalgia
Official title: The Efficacy of Reiki in the Treatment of Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Fibromyalgia
Keywords: Fibromyalgia, Reiki, Energy Medicine
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2003-01-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effectiveness of Reiki in the treatment of fibromyalgia (FM), a condition characterized by widespread muscle pain and stiffness, often accompanied by sleep disturbance, headaches, irritable bowel syndrome, and psychological distress. Reiki is a form of energy medicine in which practitioners reportedly access universal life energy to heal patients, either by direct contact at specific hand positions or from a distance.

Detailed description: Fibromyalgia is one of the most common rheumatologic diagnoses. Treatment is generally unsatisfactory and most randomized, controlled treatment trials have been unable to demonstrate a sustained effective intervention. A vast body of anecdotal literature as well as two randomized controlled trials suggest that Reiki may be an effective treatment for FM, appearing to relieve pain and improve psychological well being. Reiki appears to have no adverse effects and can eventually be self-administered, making it a low-risk, low-cost, potentially patient-empowering intervention. This study will investigate the efficacy of Reiki in the treatment of FM.

One hundred Reiki-naive FM patients will be recruited from a chronic fatigue referral clinic and will participate in an 8-week trial. Patients will be randomized into one of two Reiki groups (direct-contact and distant Reiki) or one of two control groups (sham and placebo). Patients will receive either Reiki or placebo 16 times during the course of the study. Patients will be assessed at study entry, at Weeks 4 and 8, and 12 weeks post-treatment.

Eligibility criteria: Inclusion Criteria

* Fibromyalgia without concurrent medical conditions associated with chronic pain, such as diabetic neuropathy, systemic lupus erythematosus, or severe degenerative joint disease
* Willing to undergo randomization and attend treatments regularly
* Willing to stay on a stable medical regimen during the entire 8-week trial and use only acetaminophen for breakthrough pain
* Live within a one-hour drive of the study site

Exclusion Criteria

* Received Reiki or any other energy medicine (Therapeutic Touch, Qi Gong, SHEN Therapy, etc.)
* Pregnant
* Pending litigation or disability claim related to FM

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Univ of WA - CFS/FM Research Center
state: Washington
Study officials:
affiliation: University of Washington
name: Dedra S. Buchwald
role: PRINCIPAL_INVESTIGATOR
References: